Literature DB >> 608821

Experimental studies on factors causing acute serum sickness glomerulonephritis of immune complex origin. I. The role of immune complexes and the immunological status of the host.

T Szabó, J Szabó, A Lenkey, L Kovács, C Balázs.   

Abstract

In acute serum sickness glomerulonephritis induced in rabbits by large doses of BSA, the relationship of the host's immunological status and the severity of renal histological changes was studied. It was found that good antibody producers developed more severe renal lesions. The higher avidity of antibodies enhances the inflammatory effect of immune complexes. Kidney is favoured for deposition of immune complexes especially in the case of chronic immune complex formation in the presence of antigen excess. Diminished phagocytic function of leukocytes (probably decreased immune complex saturating capacity) may also contribute to the severity of renal histological alterations.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 608821     DOI: 10.1007/bf02082173

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  20 in total

1.  The relationships between the chemical nature of the antigen, antigen dosage, rate of antibody synthesis and the occurrence of arteritis and glomerulonephritis in experimental hypersensitivity.

Authors:  F G GERMUTH; C FLANAGAN; M R MONTENEGRO
Journal:  Bull Johns Hopkins Hosp       Date:  1957-09

2.  Pathogenesis of serum sickness.

Authors:  F J DIXON; J J VAZQUEZ; W O WEIGLE; C G COCHRANE
Journal:  AMA Arch Pathol       Date:  1958-01

3.  A method of trace iodination of proteins for immunologic studies.

Authors:  P J McConahey; F J Dixon
Journal:  Int Arch Allergy Appl Immunol       Date:  1966

Review 4.  Immunopathology and glomerulonephritis.

Authors:  C B Wilson; F J Dixon
Journal:  Annu Rev Med       Date:  1974       Impact factor: 13.739

5.  Antigen quantitation in experimental immune complex glomerulonephritis. I. Acute serum sickness.

Authors:  C B Wilson; F J Dixon
Journal:  J Immunol       Date:  1970-08       Impact factor: 5.422

6.  Determination of soluble immune complex molar composition and antibody association constants by ammonium sulfate precipitation.

Authors:  W P Arend; M Mannik
Journal:  J Immunol       Date:  1974-02       Impact factor: 5.422

7.  Immune complex disease. V. The nature of the circulating complexes associated with glomerular alterations in the chronic BSA-rabbit system.

Authors:  F G Germuth; L B Senterfit; G R Dreesman
Journal:  Johns Hopkins Med J       Date:  1972-06

8.  Quantitation of acute and chronic serum sickness in the rabbit.

Authors:  C B Wilson; F J Dixon
Journal:  J Exp Med       Date:  1971-09-01       Impact factor: 14.307

9.  The localization of circulating immune complexes in experimental serum sickness. The role of vasoactive amines and hydrodynamic forces.

Authors:  W T Kniker; C G Cochrane
Journal:  J Exp Med       Date:  1968-01-01       Impact factor: 14.307

10.  A receptor for the third component of complement in the human renal glomerulus.

Authors:  M C Gelfand; M M Frank; I Green
Journal:  J Exp Med       Date:  1975-10-01       Impact factor: 14.307

View more
  3 in total

1.  Experimental glomerular lesions induced by chronic immune complex formation. I. Formation and elimination of the immune complex (relationship between the immune status and the glomerular changes).

Authors:  T Szabó; J Szabó; C Balázs; G Lustyik
Journal:  Int Urol Nephrol       Date:  1979       Impact factor: 2.370

2.  Experimental glomerular lesions induced by chronic immune complex formation. II. Pathomorphological analysis.

Authors:  J Szabó; T Szabó; T Tóth; G Lustyik; C Balázs
Journal:  Int Urol Nephrol       Date:  1979       Impact factor: 2.370

3.  Experimental studies on factors causing acute serum sickness glomerulonephritis of immune complex origin. II. Pathomorphological analysis.

Authors:  J Szabó; T Szabó; G Lustyik; A Lenkey
Journal:  Int Urol Nephrol       Date:  1977       Impact factor: 2.370

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.